Tiltbio has multiple oncolytic viral therapies for solid tumors in its pipeline. The lead investigational asset, TILT-123, is a cytokine-armed oncolytic adenovirus for ovarian cancer currently in Phase II development in the U.S. in combination with pembrolizumab, an immune checkpoint inhibitor.
Additionally, Phase Ib studies of TILT-123 in various indications continue in Europe and the U.S. both as a monotherapy and in combination with immune checkpoint inhibitors or tumor-infiltrating lymphocyte (TIL) therapy.
- Product/Program: TILT-123; Ovarian cancer (NCT05271318)
- Indication: Ovarian Cancer
- Description: Collaboration with Merck & Co (MSD) for the use of pembrolizumab (anti-PD-1)
- Development status: Phase Ib/II trials; Rochester (MN, USA), Feinstein (NY, USA), Docrates Cancer Centre (Finland)
- Next milestone(s): 2025: Phase II start
- Product/Program: TILT-123; Melanoma (NCT04217473, NCT06961786)
- Indication: Melanoma
- Description: TILT-123 in combination with TIL therapy
- Development Status: Phase Ib trial; Herlev (Denmark)
- Next milestone(s): 2025: Phase Ib start
- Product/Program: TILT-123; Lung cancer (NCT06125197)
- Indication: Lung Cancer
- Description: Collaboration with Merck MSD for the use of pembrolizumab (anti-PD-1)
- Development status: Phase I trial; Hoag (CA, USA), UCLA (CA, USA)
- Next milestone(s): 2026: Phase I finalized
- Product/Program: TILT-123; Head & neck cancer (NCT05222932)
- Indication: Head and Neck Cancer and Melanoma
- Description: Collaboration with Merck for the use of avelumab (anti-PD-L1)
- Development status: Phase I trials; New York City (NY, USA), Docrates Cancer Centre (Finland)
- Next milestone(s): 2026: Phase I finalized
- Product/Program: TILT-123; Solid tumors (NCT04695327)
- Indication: Solid Tumors (EU)
- Description: Phase I monotherapy safety for TILT-123
- Development status: Phase I trial; Helsinki University Hospital (Finland), Docrates Cancer Centre (Finland)
- Next milestone(s): 2025: Phase Ib finalized
- Product: TILT-322 Ad5/3 chimeric with next generation payload
- Indication: Solid Tumors
- Description: T-cell recruitment into tumors and local activation. Local delivery of bispecific antibody and cytokine.
- Development status: Pre-clinical
- Product: TILT-234 Ad3
- Indication: Solid tumors
- Description: Enabling technology for Dendritic cell therapy. Available for out-licensing.
- Development status: Pre-clinical
-
TILT-234 structure: Based on Adenovirus serotype 3 (Ad3) genome that is armed with human CD40L.
Our Technology
The power of TILT® technology enables Tiltbio’s proprietary oncolytic viruses to be encoded with immunostimulatory cytokines and molecules, which have potential applicability across a wide range of solid tumor cancers.
Learn more about how Tiltbio’s technology works: